rxpertusa logo spacer rxpertusa wings
logo spacer spacer spacer
spacer home
about us
assessment tools
sample consult
acps services
contact us
favorite links

red line

spacer spacer news

The latest Mainline newsletters for the General Public are listed here.


For healthcare professionals we have a Mainline newsletter in a Professional version here.

Printer Friendly


Volume 3 August 24, 2006 Number 7

An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate

Medication News & Update

Weight-based, fixed-dose, unmonitored subcutaneous unfractionated heparin administered twice daily found to be equivalent to low molecular weight heparin for treatment of DVT and PE


Investigators in Canada and New Zealand randomized a total of 708 DVT and/or PE patients to twice daily, fixed dose unfractionated heparin (333 U/Kg load followed by 250 U/kg q 12 hrs) or twice daily subcutaneous LMWH (100 U/kg q 12 hrs - approximately 75% received dalteparin and 25% enoxaparin). Most patients (approx. 70% in each group) - including PE patients - were treated as outpatients. The trial was open-label but end points were adjudicated by a board that was blinded to treatment. There was no significant difference in recurrent VTE (3.8% with UFH vs. 3.4% with LMWH), major bleed (1.1% with UFH vs. 1.4% with LMWH), and deaths (18 in UFH vs 22 with LMWH).

The complete posting and a link to the full text of the article referenced is available on ClotCare at http://www.clotcare.com/clotcare/ufhvslmwhfordvtpe.aspx [2].




Home ] [ About Us  ] [ Assessment Tools  ] [ Sample Consult  ]
Contact Us  ] [ Favorite Links  ]

Copyright © www.rxpertusa.com. Designed by PcHousekeeping.com
  spacer spacer